Company news

Grifols, S.A. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Grifols S A signs renewable energy purchase agreement with ENGIE to cover more than half of its electricity consumption in Spain

September 16, 2026

Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency

August 10, 2026

Grifols S A doses first patients in two Phase 3 trials to expand indications of its flagship immunoglobulins

July 16, 2026

Grifols S A doses first participant in Phase 3 study evaluating novel subcutaneous therapy for alpha1-antitrypsin deficiency

June 29, 2026

Shareholders approve key resolutions at the 2026 Annual General Shareholders’ Meeting

June 18, 2026

Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.

June 15, 2026

Grifols: Egypt continues its growth plan through 2029 with an additional investment of €180 million

June 12, 2026

Grifols Supports AlphaDetect to Accelerate Detection of Alpha-1

June 5, 2026

Grifols S A breaks ground on new manufacturing site in Spain

June 3, 2026

Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson’s Disease

March 17, 2026

Health Coalition demands disclosures & end to Grifols’ for-profit blood plasma contract following reports of deaths, harm, non-compliance

March 13, 2026

Media Advisory: Press Conference Regarding Tragic Deaths After Plasma Harvesting at Grifols’ Sites

March 12, 2026

Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years

July 1, 2024

Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies

June 17, 2024

Procleix ArboPlex Assay® di Grifols, primo e unico test NAT 4-in-1 per lo screening degli arbovirus, riceve il marchio CE

April 4, 2024

Procleix ArboPlex Assay® da Grifols recebe a marca CE, o primeiro e único NAT 4 em 1 para o rastreio de arbovírus

April 4, 2024

Le test Procleix ArboPlex Assay® de Grifols, test de Dépistage Génomique Viral 4-en-1 destiné au dépistage des arbovirus, reçoit le marquage CE

April 4, 2024

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

April 4, 2024

Grifols Procleix ArboPlex Assay® erhält die CE-Zertifizierung – der erste und einzige 4-in-1-Nukleinsäuretest zum Nachweis von Arboviren

April 4, 2024

Grifols announces positive topline phase 3 fibrinogen clinical trial results

February 14, 2024

Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and Analytics

August 1, 2023

Calls

The 5 newest of 13 calls. Every call is listed under its year.

Decks

The 5 newest of 29 decks. Every deck is listed under its year.